Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research and development, production, and sales of chemical raw materials and pharmaceutical preparations in China. The company provides drugs for the treatment of anemia, mental disorders, anti-psychotic disorders, cardiovascular and cerebrovascular diseases, and tumors. It provides drugs in the form of tablets and … Read more
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd (301130) - Net Assets
Latest net assets as of September 2025: CN¥947.42 Million CNY
Based on the latest financial reports, Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd (301130) has net assets worth CN¥947.42 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.05 Billion) and total liabilities (CN¥105.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥947.42 Million |
| % of Total Assets | 89.96% |
| Annual Growth Rate | 16.1% |
| 5-Year Change | 99.35% |
| 10-Year Change | 384.08% |
| Growth Volatility | 25.54 |
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd (2011–2024)
The table below shows the annual net assets of Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥941.16 Million | -4.24% |
| 2023-12-31 | CN¥982.86 Million | +3.97% |
| 2022-12-31 | CN¥945.29 Million | +80.35% |
| 2021-12-31 | CN¥524.14 Million | +11.02% |
| 2020-12-31 | CN¥472.12 Million | +5.71% |
| 2019-12-31 | CN¥446.62 Million | +8.88% |
| 2018-12-31 | CN¥410.19 Million | +7.68% |
| 2017-12-31 | CN¥380.95 Million | +66.35% |
| 2014-12-31 | CN¥229.00 Million | +17.79% |
| 2013-12-31 | CN¥194.42 Million | +20.12% |
| 2012-12-31 | CN¥161.86 Million | +19.74% |
| 2011-12-31 | CN¥135.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1436.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥391.72 Million | 43.25% |
| Common Stock | CN¥80.80 Million | 8.92% |
| Other Comprehensive Income | CN¥73.01 Million | 8.06% |
| Other Components | CN¥360.21 Million | 39.77% |
| Total Equity | CN¥905.75 Million | 100.00% |
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd Competitors by Market Cap
The table below lists competitors of Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ocean Plastics Co Ltd
TW:1321
|
$168.69 Million |
|
AIRO Group Holdings, Inc. Common Stock
NASDAQ:AIRO
|
$168.72 Million |
|
AVITA MEDICAL DL-0001
F:51KA
|
$168.74 Million |
|
Seah Steel Corp
KO:003030
|
$168.76 Million |
|
Deceuninck N.V.
LSE:0MEL
|
$168.66 Million |
|
Echoiq Ltd
AU:EIQ
|
$168.60 Million |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
$168.57 Million |
|
Ricardo plc
F:RIR
|
$168.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 982,863,414 to 905,746,474, a change of -77,116,940 (-7.8%).
- Net income of 40,268,798 contributed positively to equity growth.
- Dividend payments of 20,015,394 reduced retained earnings.
- Share repurchases of 100,013,941 reduced equity.
- Other comprehensive income increased equity by 6,908,471.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥40.27 Million | +4.45% |
| Dividends Paid | CN¥20.02 Million | -2.21% |
| Share Repurchases | CN¥100.01 Million | -11.04% |
| Other Comprehensive Income | CN¥6.91 Million | +0.76% |
| Other Changes | CN¥-4.26 Million | -0.47% |
| Total Change | CN¥- | -7.85% |
Book Value vs Market Value Analysis
This analysis compares Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.67x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.13x to 2.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥3.06 | CN¥31.02 | x |
| 2012-12-31 | CN¥3.00 | CN¥31.02 | x |
| 2013-12-31 | CN¥3.57 | CN¥31.02 | x |
| 2014-12-31 | CN¥4.23 | CN¥31.02 | x |
| 2017-12-31 | CN¥6.64 | CN¥31.02 | x |
| 2018-12-31 | CN¥6.77 | CN¥31.02 | x |
| 2019-12-31 | CN¥7.37 | CN¥31.02 | x |
| 2020-12-31 | CN¥5.84 | CN¥31.02 | x |
| 2021-12-31 | CN¥6.49 | CN¥31.02 | x |
| 2022-12-31 | CN¥11.70 | CN¥31.02 | x |
| 2023-12-31 | CN¥12.16 | CN¥31.02 | x |
| 2024-12-31 | CN¥11.64 | CN¥31.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.71%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.17x
- Recent ROE (4.45%) is below the historical average (12.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 20.90% | 24.42% | 0.51x | 1.68x | CN¥14.74 Million |
| 2012 | 23.01% | 24.62% | 0.63x | 1.48x | CN¥21.06 Million |
| 2013 | 20.74% | 20.92% | 0.68x | 1.46x | CN¥20.88 Million |
| 2014 | 22.23% | 25.01% | 0.72x | 1.24x | CN¥28.02 Million |
| 2017 | 11.98% | 16.68% | 0.58x | 1.24x | CN¥7.53 Million |
| 2018 | 10.08% | 14.76% | 0.56x | 1.22x | CN¥341.70K |
| 2019 | 12.23% | 16.81% | 0.61x | 1.19x | CN¥9.95 Million |
| 2020 | 10.54% | 17.37% | 0.52x | 1.17x | CN¥2.53 Million |
| 2021 | 9.92% | 18.21% | 0.48x | 1.13x | CN¥-394.71K |
| 2022 | 4.31% | 15.94% | 0.25x | 1.08x | CN¥-53.81 Million |
| 2023 | 5.14% | 22.40% | 0.21x | 1.09x | CN¥-47.78 Million |
| 2024 | 4.45% | 15.71% | 0.24x | 1.17x | CN¥-50.31 Million |
Industry Comparison
This section compares Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd (301130) | CN¥947.42 Million | 20.90% | 0.11x | $168.69 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |